Functionalized liposomes for targeted breast cancer drug delivery
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Despite the exceptional progress in breast cancer pathogenesis, prognosis, diagnosis, and treatment strategies, it remains a prominent cause of female mortality worldwide. Additionally, although chemotherapies are effective, they are associated with critical limitations, most notably their lack of specificity resulting in systemic toxicity and the eventual development of multi-drug resistance (MDR) cancer cells. Liposomes have proven to be an invaluable drug delivery system but of the multitudes of liposomal systems developed every year only a few have been approved for clinical use, none of which employ active targeting. In this review, we summarize the most recent strategies in development for actively targeted liposomal drug delivery systems for surface, transmembrane and internal cell receptors, enzymes, direct cell targeting and dual-targeting of breast cancer and breast cancer-associated cells, e.g., cancer stem cells, cells associated with the tumor microenvironment, etc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 2×
“Stealth hinders MPS clearance mechanisms resulting in improved vascular circulation time and pharmacokinetic properties of PEGylated delivery systems thus Doxil®/Caelyx® has an approximate ~100-fold greater clearance half-life than free DOX [39,85,101].”
BackgroundDrug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340 · cited 1×
“which resides in the plasma wall of tumoral cells and is overexpressed in 40–50% of breast cancer patients [31].”
BackgroundProgress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220 · cited 2×
“may result in a positive response initially but could promote clone selection leading to MDR and resistant tumor relapse [407].”
BackgroundLongmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149 · cited 2×
“the vascular system of the body with eventual elimination and clearance by the renal and mononuclear phagocytic systems (MPS) (also referred to as the reticuloendothelial system (RES)) [96,97].”
BackgroundA highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)
Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., & Springer, T. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1101 · Cited by 1,482
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Hyaluronan as an Immune Regulator in Human Diseases
Jiang, D., Liang, J., & Noble, P. W. (2011) · Physiological Reviews · doi:10.1152/physrev.00052.2009 · Cited by 1,060
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695
Mahmood, N., Mihalcioiu, C., & Rabbani, S. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00024 · Cited by 478
Structure of the human LAT1–4F2hc heteromeric amino acid transporter complex
Yan, R., Zhao, X., Lei, J., & Zhou, Q. (2019) · Nature · doi:10.1038/s41586-019-1011-z · Cited by 358
Global analysis of advanced/metastatic breast cancer: decade report (2005-2015)
Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J., Cardoso, M.-J., Peccatori, F., Paonessa, D., Benares, A., et al. (2018) · The Breast · doi:10.1016/j.breast.2018.03.002 · Cited by 324 · cited 1×
“more likely to succumb to the metastatic tumors than the primary tumor [37,38].”
BackgroundLv, Y., Xu, C., Zhao, X., Lin, C., Yang, X., Xin, X., Zhang, L., Qin, C., Han, X., Yang, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08051 · Cited by 235 · cited 12×
“MMPs facilitate angiogenesis and wound healing via their ability to break down and remodel almost every component of the ECM in normal tissues, and their dysregulation has been implicated in cardiovascular diseases, inflammatory disorders, and cancer [337].”
BackgroundInfluentialNeuropilin 1: function and therapeutic potential in cancer
Chaudhary, B., Khaled, Y. S., Ammori, B. J., & Elkord, E. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1500-0 · Cited by 233 · cited 4×
“Neuropilin 1 Neuropilin 1 (NRP1) is a transmembrane glycoprotein co-receptor for certain isoforms of semaphorins, VEGF, and TGF-β [316].”
BackgroundInfluentialA pharmacological review of selective oestrogen receptor modulators
Goldstein, S. R. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.3.212 · Cited by 205
Liscovitch, M., & Ravid, D. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.01.013 · Cited by 152
Dufès, C., Al Robaian, M., & Somani, S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.21 · Cited by 110
A7RC peptide modified paclitaxel liposomes dually target breast cancer
Cao, J., Wang, R., Gao, N., Li, M., Tian, X., Yang, W., Ruan, Y., Zhou, C., Wang, G., Liu, X., et al. (2015) · Biomaterials Science · doi:10.1039/c5bm00161g · Cited by 93 · cited 3×
“TNBC MDA-MB-231, 4T1 MCF-7, SUIT-2 [204,205]”
BackgroundEPR Effect-Based Tumor Targeted Nanomedicine: A Promising Approach for Controlling Cancer
Fang, J. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010095 · Cited by 31 · cited 1×
“the use of strategies to; standardize and analyze the EPR effect in solid tumors; identify, image and track tumor vascularization; and reduce the clearance of therapeutic nanomedicines by the liver, kidneys, lungs, and spleen thus allowing enhanced accumulation in the tumor [406].”
Method
Cited by
Polymer-Based Hydrogels Applied in Drug Delivery: An Overview
Thang, N. H., Chien, T. B., & Cuong, D. X. (2023) · Gels · doi:10.3390/gels9070523 · Cited by 812
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects
Imtiaz, S., Ferdous, U. T., Nizela, A., Hasan, A., Shakoor, A., Zia, A. W., & Uddin, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117535 · Cited by 119
Metadata
- Authors
- Nel, J., Elkhoury, K., Velot, É., Bianchi, A., Acherar, S., Francius, G., Tamayol, A., Grandemange, S., & Arab-Tehrany, E.
- Venue
- Bioactive Materials
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 24
- Pages
- 401-437
- ISSN
- 2097-1192 (ISSN-L)
- 2452-199X
- OpenAlex
- W4313479611
- Cited by
- 182
- References
- 26
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.